Skip to main content
Premium Trial:

Request an Annual Quote

MDNA Taps Phi Life Sciences to Distribute Prostate Cancer Liquid Biopsy Test in US

NEW YORK (GenomeWeb) – Molecular diagnostics firm MDNA Life Sciences said today that it signed an agreement making Phi Life Sciences the first US distributor of its proprietary liquid biopsy test for prostate cancer, the Prostate Mitomic Test (PMT).

MDNA has pioneered a method for liquid biopsy testing based on analysis of the mitochondrial genome. PMT is a liquid biopsy test intended to determine which men with clinical suspicion of prostate cancer are likely to have high-grade disease that may require immediate intervention. The test's negative predictive value can also help identify cases that can safely delay or forego immediate biopsy.

"Launching PMT with Phi will allow us to quickly build a user base to drive market acceptance and adoption," said MDNA CEO Chris Mitton in a statement. "This valuable partnership will also help with the collection of post-market data for PMT to demonstrate clinical utility."

In addition to the prostate cancer test, MDNA is also working on a test for endometriosis. It formed a collaboration earlier this month with the University of Oxford to further develop and validate this assay.